Open Access
Issue
BioMedicine
Volume 8, Number 4, December 2018
Article Number 26
Number of page(s) 5
DOI https://doi.org/10.1051/bmdcn/2018080426
Published online 26 November 2018
  1. Claes D, Jackson E. Cystinuria: mechanisms and management. Pediatr Nephrol. 2012; 27: 2031–8. [CrossRef] [PubMed] [Google Scholar]
  2. Goodyer P. The Molecular Basis of Cystinuria. Nephron Exp Nephrol. 2004; 98: e45–e49. [CrossRef] [PubMed] [Google Scholar]
  3. Christopher NG, Stevan S. Contemporary Management of Cystinuria. J Endourology. 1999; 13(9): 647–53. [CrossRef] [Google Scholar]
  4. Milliner DS, Murphy ME. Urolithiasis in pédiatrie patients (see comments). Mayo Clin Proc. 1993; 68: 241. [CrossRef] [PubMed] [Google Scholar]
  5. Polinsky MS, Kaiser BA, Blauarte HJ. Urolithiasis in childhood. Pediatr Clin North Am. 1987; 34: 683. [CrossRef] [PubMed] [Google Scholar]
  6. Lee M. cystine growth Inhibition through molecular mimicry: a New Paradigm for the Prevention of Crystal Diseases. Curr Rheumatol Rep. 2015; 17(5): 33. [CrossRef] [PubMed] [Google Scholar]
  7. Gambaro G, Favaro S, D’Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis. 2001; 37(233): 243. [CrossRef] [Google Scholar]
  8. Simfroush N, Alizadeh A. Urology. 2017; 1–100. [Google Scholar]
  9. Evan A, FLCoe F, Lingeman JE. Renal crystal deposit and histopathology in patients with cystin stone. Kidney International. 2006; 69: 2227–35 [CrossRef] [PubMed] [Google Scholar]
  10. Leusmann DB, Niggemann H, Roth S, von Ahlen H. Recurrence rates and severity of urinary calculi. Scand J Urol Nephrol. 1995; 29: 279–83. [CrossRef] [PubMed] [Google Scholar]
  11. Leusmann DB, Blaschke R, Schmandt W. Results of 5035 stone analyses: a contribution to epidemiology of urinary stone disease. Scand J Urol Nephrol. 1990; 24: 205–10. [CrossRef] [PubMed] [Google Scholar]
  12. Harperin E. The Use of D-Penicillamine in Cystinuria: Efficacy and Untoward Reactions. The Year Journal pof biology and medicine. 1981; 54: 439–46. [Google Scholar]
  13. Daudon M, Cohen-Solal F. Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res. 2003; 31: 207–11. [CrossRef] [PubMed] [Google Scholar]
  14. Sakly R, Chaouch A. Effects of intraperitoneally administered vitamin E and selenium on calcium oxalate renal stone formation: experimental study in rat. Annales d’urologie. 2003; 37: 47–50. [Google Scholar]
  15. Jacob C. Sulfur and Selenium: The role of oxidation state in protein structure and function. Angew. Chem. Int. Ed. 2003; 42: 4742–58. [CrossRef] [Google Scholar]
  16. Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol. [Google Scholar]
  17. Wollaston WH. On cystic oxide, a new species of urinary calculus. Philos Trans R Soc Lond. 1810; 100: 223–30. [CrossRef] [Google Scholar]
  18. Liu Y, Xu H. Wenting Zhong, Qingpeng Shen. Organic Selenium Alleviated the Formation of Ethylene Glycol-Induced Calcium Oxalate Renal Calculi by Improving Osteopontin Expression and Antioxidant Capability in Dogs. Biol Trace Elem Res. 2015; 168: 392400. [Google Scholar]
  19. Slojewski M. Major and trace elements in lithogenesis. Central European Journal of rology. 2011; 64: 2–8. [Google Scholar]
  20. Chrzan P, Ramaswamy K. MP34-06 inhibition of nucleation and growth of cystin crystal in urine. The Journal of Urology. 2015; 193(4s): e412–e413. [CrossRef] [Google Scholar]
  21. Singh V, Pradeep K, Rai P. Kidney stone analysis techniques and the role of major and trace elements on their pathogenesis: a review. Biophys Rev. 2014; 6: 291–310. [CrossRef] [PubMed] [Google Scholar]
  22. Ludwig Strohmaier W. Reduction of high-energy shock-wave- induced renal tubular injury by selenium. Urol Res. 1999; 27: 382–5. [CrossRef] [PubMed] [Google Scholar]
  23. Liu Y, Xu H. Organic Selenium Alleviated the Formation of Ethylene Glycol-Induced Calcium Oxalate Renal Calculi by Improving Osteopontin Expression and Antioxidant Capability in Dogs. Biol Trace Elem Res. 2015; 168: 392–400. [CrossRef] [Google Scholar]
  24. Mani SK, Ramasamy S. Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. Nutr Biochem. 2003; 14: 306–13. [CrossRef] [Google Scholar]
  25. Grases F, Garcia FL, Costa BA. Development of calcium oxalate crystals on urothelium effect of free radical. Nephron. 1998; 78: 296–301. [CrossRef] [PubMed] [Google Scholar]
  26. Selvam R. Calcium oxalate stone disease: role of lipid peroxidation and antioxidants. Urol Res. 2002; 30: 35–47. [CrossRef] [PubMed] [Google Scholar]
  27. Adhirai M, Selvam R. Effect of cyclosporin on liver antioxidants and the protective role of vitamin E in hyperoxaluria in rats. Pharm Pharmacol. 1998; 50: 501–5. [CrossRef] [Google Scholar]
  28. Anbazhagan M, Hariprasad C. Samudram P, Latha E, Latha M, Sel- vam R. Effect of oral supplementation of vitamin E on urinary risk factors in patients with hyperoxaluria. Clin Biochem Nutr. 1999; 27: 37–47. [CrossRef] [Google Scholar]
  29. Mani SK, Ramasamy S. Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. Nutr Biochem. 2003; 14: 306–13. [CrossRef] [Google Scholar]
  30. Thamilselvan S. Menon M Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. BJU Int. 2005; 96: 117–26. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.